MANAGEMENT OF MULTI DRUG RESISTANT IN TREATMENT OF GONORRHEA: A SYSTEMATIC REVIEW
DOI:
https://doi.org/10.61841/v3fm5f64Keywords:
Multi drug resistant, gonorrheaAbstract
Background: A significant worldwide public health issue, gonorrhea is made worse by antibiotic resistance.
Aims: This systematic review is to review the treatment of gonorrhea in patients with multi drug resistant of antimicroba.
Methods: This study demonstrated compliance with all requirements by means of a comparison with the standards established by the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) 2020. Thus, the specialists were able to guarantee that the research was as current as feasible. Publications released between 2014 and 2024 were considered for this search strategy. This was accomplished by utilizing a number of distinct online reference sites, including Pubmed, ScienceDirect, and SagePub. It was determined that reviews, previously published works, and partially completed works would not be included.
Result: In the PubMed database, the results of our search brought up 4.511 articles, whereas the results of our search on SCIENCE DIRECT brought up 1.110 articles, our search on SAGEPUB brought up 1.738 articles. The results of the search conducted for the last year of 2014 yielded a total 1.464 articles for PubMed, 265 articles for SCIENCE DIRECT and 684 articles for SAGEPUB. In the end, we compiled a total of 5 papers, 3 of which came from PubMed, 1 of which came from SCIENCE DIRECT and 1 of which came from SAGEPUB. We included five research that met the criteria.
Conclusion: In summary, globally, the prevalence of gonococcal infections is growing quickl. Most concerningly, N.
gonorrhoeae is a significant contributor to the bacterial population that disseminates resistance to antibiotics.
References
Fifer H, Natarajan U, Jones L, Alexander S, Hugher G, Golparian D, et al. Failure of Dual Antimicrobial Therapy in Treatment of Gonorrhea. N Engl J Med. 2016;374(25):2504–6.
Paz-Bailey G, Mendoza MCB, Finlayson T, Wejnert C, Le B, Rose C, et al. Trends in condom use among MSM in the United States: The role of antiretroviral therapy and seroadaptive strategies. AIDS. 2016 Jul 31;30(12):1985–90.
Newman L, Rowley J, Hoorn S Vander, Wijesooriya NS, Unemo M, Low N, et al. Global Estimates of the Prevalence and Incidence of Four Curable Sexually Transmitted Infections in 2012 Based on Systematic Review and Global Reporting. Vol. 10, PLoS ONE. Public Library of Science; 2015.
Alirol E, Wi TE, Bala M, Bazzo ML, Chen XS, Deal C, et al. Multidrug-resistant gonorrhea: A research and development roadmap to discover new medicines. Vol. 14, PLoS Medicine. Public Library of Science; 2017.
Tsevat DG, Wiesenfeld HC, Parks C, Peipert JF. Sexually transmitted diseases and infertility. Vol. 216, American Journal of Obstetrics and Gynecology. Mosby Inc.; 2017. p. 1–9.
Donders GGG, Desmyter J, De Wet DH, Van Assche FA. The association of gonorrhoea and syphilis with premature birth and low birthweight. Genitourin Med. 1993;69(2):98–101.
van Liere GAFS, Hoebe CJPA, Duker-Muijrers NHTM. Evaluation of the anatomical site distribution of chlamydia and gonorrhoea in men who have sex with men and in high-risk women by routine testing: crosssectional study revealing missed opportunities for treatment strategies. Sex Transm Infect. 2014;90(1):58–60.
Unemo M, Shafer WM. Antimicrobial resistance in Neisseria gonorrhoeae in the 21st Century: Past, evolution, and future. Clin Microbiol Rev. 2014;27(3):587–613.
Grad YH, Harris SR, Kirkcaldy RD, Green AG, Marks DS, Bentley SD, et al. Genomic epidemiology of gonococcal resistance to extended-spectrum cephalosporins, macrolides, and fluoroquinolones in the United States, 2000-2013. Journal of Infectious Diseases. 2016 Nov 15;214(10):1579–87.
Rice LB. Will use of combination cephalosporin/azithromycin therapy forestall resistance to cephalosporins in Neisseria gonorrhoeae? Sex Transm Infect. 2015;91(4):238–40.
Queirós C, Borges Da Costa J, Lito L, Filipe P, Melo Cristino J. Gonorrhea in a Tertiary Care Portuguese Hospital: A 10-year Retrospective Study of the Evolution of Cases and Drug Resistance of the Isolates. Vol. 111, Actas Dermosifiliogr. 2020.
Kirkcaldy RD, Weinstock HS, Moore PC, Philip SS, Wiesenfeld HC, Papp JR, et al. The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea. Clin Infect Dis. 2014;59(8):1083–91.
de Vries HJ, de Laat M, Jongen VW, Heijman T, Wind CM, Boyd A, et al. Efficacy of ertapenem, gentamicin, fosfomycin, and ceftriaxone for the treatment of anogenital gonorrhoea (NABOGO): a randomised, noninferiority trial. Lancet Infect Dis. 2022;22(5):706–17.
Ross JD, Harding J, Duley L, Montgomery AA, Hepburn T, Tan W. Gentamicin as an alternative to ceftriaxone in the treatment of gonorrhoea: the G-TOG non-inferiority RCT. Health Technol Assess. 2019;23(20):1–104.
Petousis-Harris H, Paynter J, Morgan J, Saxton P, McArdle B, Goodyear-Smith F, et al. Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study. Lancet. 2017;390(10102):1603–10.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
